Project Grant R43HL154960

Federal Project Grant Award Summary Airalux Medical, Inc. received a $306,872 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 5, 2025, with completion targeted for January 4, 2027. The company is developing a digitally-enabled incentive spirometry device designed to improve patient adherence to post-surgical respiratory therapy and streamline clinical workflows. The device automatically...

Federal Grant Award Summary Respair, Inc. received a $305,218 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion scheduled for August 31, 2027. The company is developing AssuranceET, a novel pediatric endotracheal tube (ETT) designed to replace traditional inflatable balloon cuff mechanisms with ultra-soft micro-baffles—thin, flexible discs that create airway...

Grant Award Summary Heartpoint Global Inc. received a $1.77M Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through August 31, 2027. The funding supports the development and preparation for first-in-human clinical testing of the INTELLISTENT system, a minimally invasive, adjustable pulmonary flow restrictor designed to treat pediatric and congenital heart disease (CHD)...

Federal Project Grant Award Summary Perfusion Solutions Inc. received a $320,838 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, with completion targeted for February 28, 2027. The award supports Phase I development of a fail-safe, high-output cavopulmonary assist pump designed for pediatric and congenital heart disease patients with single ventricle physiology...

Federal Project Grant Award Summary Aptus, LLC received a $965,037 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) awarded September 1, 2025, with completion anticipated August 31, 2027. The project deliverables focus on the development and preclinical testing of an expandable pediatric pulmonary heart valve designed to address a critical clinical gap in congenital heart valve disease treatment....

Federal Project Grant Award Summary SafeBVM Corp. received a $499,932 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 17, 2025, with completion targeted for August 31, 2026. The award funds the development and integration of SafeBVM's SOTAIR device with capnography technology to standardize manual ventilation technique and improve patient outcomes in emergency care settings. SOTAIR is a...

This Project Grant award from the National Science Foundation (NSF) under the Partnerships for Innovation - Research Partnerships (PFI-RP) program supports the development of a virtual human testing platform for inhaler innovation and drug delivery optimization. The $549,999 project, awarded on August 1, 2023 and running through July 31, 2026, aims to create an AI-assisted virtual platform that can accurately simulate airflow, aerosolized medication delivery, and drug translocation in both...

Federal Grant Award Summary Massachusetts General Hospital's Research Management Division received a $1,519,316 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through June 30, 2029. The award funds development and clinical validation of mechanomicroscopy, an innovative endoscopic imaging platform designed to enable transbronchial assessment of pulmonary hypertension (PH)...

Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...

Federal Grant Award Summary Spheric Bio Inc. received a $598,636 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 25, 2025, with completion targeted for September 14, 2027. The company is developing the EMULAATE platform, a minimally-invasive technology that assembles fully-soft, patient-specific implants directly within the patient's body to occlude the left atrial appendage (LAA) for...